Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | PLAU | P00749 | 1/20 | 0.57 |
| ▸ | HPN | P05981 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2636629 | 1.00 | ALDH1A1 (0.68) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL696505 | 1.00 | ALDH1A1 (0.68) | ALDH1A1HTTGAAHPGDPOLB | |
| Hydrochloric Acid SCHEMBL4077466 | 0.98 | ALDH1A1 (0.67) | ALDH1A1HTTGAAHPGDPOLB | |
| Water SCHEMBL5497101 | 0.98 | ALDH1A1 (0.67) | ALDH1A1HTTGAAHPGDPOLB | |
| Hydrochloric Acid SCHEMBL4077465 | 0.98 | ALDH1A1 (0.67) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL6302459 | 0.96 | ALDH1A1 (0.64) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL5702221 | 0.92 | ALDH1A1 (0.62) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL5702094 | 0.92 | ALDH1A1 (0.62) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL4669530 | 0.92 | ALDH1A1 (0.62) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL8446614 | 0.92 | MMP2 (0.63) | ALDH1A1HTTGAAHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 304 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119285654-A | Resolution method of tetramisole hydrochloride | 河北尚澳生物科技有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-119285523-A | Method for recovering tetramisole hydrochloride resolving agent N-p-toluenesulfonyl-L-proline | 河北尚澳生物科技有限公司 | 2025-01-10 | — | — | CN | claimed |
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | THE UNIVERSITY OF TOLEDO (US) | 2021-11-30 | — | — | US | claimed |
| US-20200270202-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | THE UNIVERSITY OF TOLEDO (US) | 2020-08-27 | — | — | US | claimed |
| WO-2017172476-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | THE UNIVERSITY OF TOLEDO (US) | 2017-10-05 | — | — | WO | claimed |
| US-8614201-B2 | Heterocyclic amides as modulators of TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-24 | — | — | US | claimed |
| US-8278454-B2 | Process for preparing tetrahydroquinoline derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-10-02 | — | — | US | claimed |
| US-20100311976-A1 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2010-12-09 | — | — | US | claimed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | claimed |
| EP-2220067-A2 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | Merck Patent GmbH (DE) | 2010-08-25 | — | — | EP | claimed |
| WO-2009077052-A2 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-06-25 | — | — | WO | claimed |
| US-7410995-B1 | N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders | GPI NIL HOLDINGS INC. (US) | 2008-08-12 | — | — | US | claimed |
| US-7045629-B2 | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane | MERCK PATENT GMBH (DE) | 2006-05-16 | — | — | US | claimed |
| EP-1383763-B1 | METHOD FOR PRODUCING 2-(-5-(4-FLUOROPHENYL)-3-PYRIDYLMETHYLAMINOMETHYL)-CHROMANE | MERCK PATENT GMBH (DE) | 2005-10-12 | — | — | EP | claimed |
| US-20040138266-A1 | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane | MERCK PATENT GMBH (DE) | 2004-07-15 | — | — | US | claimed |
| EP-1105126-A2 | SULFONAMIDES OF N-CONTAINING HETEROCYCLIC THIOESTERS FOR VISION AND MEMORY DISORDERS | GPI NIL Holdings, Inc. (US) | 2001-06-13 | — | — | EP | claimed |
| WO-2000009107-A2 | SULFONAMIDES OF N-CONTAINING HETEROCYCLIC THIOESTERS FOR VISION AND MEMORY DISORDERS | GPI NIL HOLDINGS, INC. (US) | 2000-02-24 | — | — | WO | claimed |
| EP-0420120-B1 | Optically active benzyl alcohol compound and pharmaceutical composition | HOKURIKU PHARMACEUTICAL (JP) | 1994-08-31 | — | — | EP | claimed |
| EP-0420120-A2 | Optically active benzyl alcohol compound and pharmaceutical composition | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1991-04-03 | — | — | EP | claimed |
| JP-10036327-A | — | — | None | — | — | JP | disclosed |
| JP-1287086-A | — | — | None | — | — | JP | disclosed |
| JP-9286763-A | — | — | None | — | — | JP | disclosed |
| CN-121990963-A | Synthesis method of (S) - (-) -1- (4-methoxybenzene) ethylamine and intermediate compound thereof | 沙普利斯医药(苏州)有限公司 | 2026-05-08 | — | — | CN | disclosed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| WO-2025124698-A1 | ARYL SULFONE AND SULFANONE DERIVATIVES AS OREXIN RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-06-19 | — | — | WO | disclosed |
| CN-119285523-A | Method for recovering tetramisole hydrochloride resolving agent N-p-toluenesulfonyl-L-proline | 河北尚澳生物科技有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119285654-A | Resolution method of tetramisole hydrochloride | 河北尚澳生物科技有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119285654-A | Resolution method of tetramisole hydrochloride | 河北尚澳生物科技有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119285523-A | Method for recovering tetramisole hydrochloride resolving agent N-p-toluenesulfonyl-L-proline | 河北尚澳生物科技有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119285523-A | Method for recovering tetramisole hydrochloride resolving agent N-p-toluenesulfonyl-L-proline | 河北尚澳生物科技有限公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2024216095-A1 | SYNTHESIS OF MAVORIXAFOR AND INTERMEDIATES THEREOF | X4 PHARMACEUTICALS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-117024352-A | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | VIVORIAN THERAPEUTICS N.V | 2022-03-22 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| CN-108218849-B | Novel inhibitors | 维沃永治疗公众有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114014874-A | Preparation method of mabarosavir intermediate | 中国科学院上海药物研究所 | 2022-02-08 | — | — | CN | disclosed |
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | THE UNIVERSITY OF TOLEDO (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200270202-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | THE UNIVERSITY OF TOLEDO (US) | 2020-08-27 | — | — | US | disclosed |
| EP-2608787-B1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-11-20 | — | — | EP | disclosed |
| EP-3191464-B1 | SYNTHESIS OF ISOFLAVANES AND INTERMEDIATES THEREOF | SYSTEM BIOLOGIE AG (CH) | 2019-11-06 | — | — | EP | disclosed |
| EP-3191464-B1 | SYNTHESIS OF ISOFLAVANES AND INTERMEDIATES THEREOF | SYSTEM BIOLOGIE AG (CH) | 2019-11-06 | — | — | EP | disclosed |
| CN-106795135-B | Synthesis of isoflavanes and intermediates thereof | 系统生物股份有限公司 | 2019-08-09 | — | — | CN | disclosed |
| US-20190040063-A1 | TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-02-07 | — | — | US | disclosed |
| EP-3412669-A1 | TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2018-12-12 | — | — | EP | disclosed |
| CN-108770356-A | The tricyclic compounds and its preparation of bromodomain protein inhibitor, pharmaceutical composition and purposes | 正大天晴药业集团股份有限公司 | 2018-11-06 | — | — | CN | disclosed |
| US-10030003-B2 | Synthesis of isoflavanes and intermediates thereof | SYSTEM BIOLOGIE AG (CH) | 2018-07-24 | — | — | US | disclosed |
| US-10030003-B2 | Synthesis of isoflavanes and intermediates thereof | SYSTEM BIOLOGIE AG (CH) | 2018-07-24 | — | — | US | disclosed |
| US-10030003-B2 | Synthesis of isoflavanes and intermediates thereof | SYSTEM BIOLOGIE AG (CH) | 2018-07-24 | — | — | US | disclosed |
| US-20170283389-A1 | Synthesis of Isoflavanes and Intermediates Thereof | SYSTEM BIOLOGIE AG (CH) | 2017-10-05 | — | — | US | disclosed |
| US-20170283389-A1 | Synthesis of Isoflavanes and Intermediates Thereof | SYSTEM BIOLOGIE AG (CH) | 2017-10-05 | — | — | US | disclosed |
| US-20170283389-A1 | Synthesis of Isoflavanes and Intermediates Thereof | SYSTEM BIOLOGIE AG (CH) | 2017-10-05 | — | — | US | disclosed |
| WO-2017133681-A1 | TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | 正大天晴药业集团股份有限公司 | 2017-08-10 | — | — | WO | disclosed |
| EP-3191464-A1 | SYNTHESIS OF ISOFLAVANES AND INTERMEDIATES THEREOF | System Biologie AG (CH) | 2017-07-19 | — | — | EP | disclosed |
| CN-106795135-A | Synthesis of isoflavanes and intermediates thereof | 系统生物股份有限公司 | 2017-05-31 | — | — | CN | disclosed |
| US-20170107205-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170107206-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-04-20 | — | — | US | disclosed |
| US-9522145-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-20 | — | — | US | disclosed |
| WO-2016038061-A1 | SYNTHESIS OF ISOFLAVANES AND INTERMEDIATES THEREOF | SYSTEM BIOLOGIE AG (CH) | 2016-03-17 | — | — | WO | disclosed |
| US-9216969-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-12-22 | — | — | US | disclosed |
| US-9211279-B2 | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-12-15 | — | — | US | disclosed |
| US-20150246021-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-03 | — | — | US | disclosed |
| US-20150190390-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-07-09 | — | — | US | disclosed |
| CN-103079563-B | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2015-07-08 | — | — | CN | disclosed |
| US-9012473-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-21 | — | — | US | disclosed |
| US-9000029-B2 | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-04-07 | — | — | US | disclosed |
| US-8993600-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150065500-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150057328-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-02-26 | — | — | US | disclosed |
| US-8895606-B2 | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140206689-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-24 | — | — | US | disclosed |
| US-8741933-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-03 | — | — | US | disclosed |
| US-8722704-B2 | Modulators of ATP-binding cassette-transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2423211-B1 | PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF | KANEKA CORP (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-8614201-B2 | Heterocyclic amides as modulators of TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-24 | — | — | US | disclosed |
| US-20130296364-A1 | MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130245011-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-19 | — | — | US | disclosed |
| US-20130245010-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-19 | — | — | US | disclosed |
| US-20130237568-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-12 | — | — | US | disclosed |
| US-20130237569-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-12 | — | — | US | disclosed |
| US-8507524-B2 | Modulators of ATP-binding cassette-transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-13 | — | — | US | disclosed |
| US-8487121-B2 | Chromane derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-07-16 | — | — | US | disclosed |
| EP-2608787-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-20130150424-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-06-13 | — | — | US | disclosed |
| US-8461156-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-11 | — | — | US | disclosed |
| CN-103079563-A | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2013-05-01 | — | — | CN | disclosed |
| US-8324207-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-04 | — | — | US | disclosed |
| US-8278454-B2 | Process for preparing tetrahydroquinoline derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-10-02 | — | — | US | disclosed |
| CN-102695546-A | Heterocylcic derivatives as inhibitors of glutaminyl cyclase | PROBIODRUG AG | 2012-09-26 | — | — | CN | disclosed |
| CN-1942161-B | Compositions and treatments for demyelinating diseases and paralysis by administration of remyelinating drugs | ELAN PHARM INC | 2012-05-30 | — | — | CN | disclosed |
| WO-2012025877-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-03-01 | — | — | WO | disclosed |
| EP-2423211-A1 | PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF | Kaneka Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20110312958-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-22 | — | — | US | disclosed |
| CN-102186475-A | Novel inhibitors | PROBIODRUG AG | 2011-09-14 | — | — | CN | disclosed |
| WO-2011091407-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLP (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20110172229-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-14 | — | — | US | disclosed |
| US-7973044-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7968547-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| WO-2011070585-A1 | PROCESSES FOR PREPARING RIVASTIGMINE, SALTS AND INTERMEDIATES THEREOF | SHODHANA LABORATORIES LIMITED (IN) | 2011-06-16 | — | — | WO | disclosed |
| US-20100311976-A1 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2010-12-09 | — | — | US | disclosed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-12-09 | — | — | US | disclosed |
| EP-2220067-A2 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | Merck Patent GmbH (DE) | 2010-08-25 | — | — | EP | disclosed |
| US-7745454-B2 | Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100160343-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100160341-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-7741328-B2 | Treating inflammatory diseases such as rheumatoid arthritis, multiple sclerosis or Crohn's disease; Very Late Antigen-4 (VLA-4), also called alpha 4 beta 1 integrin; N-(sulfonamido-substituted pyrimidyl, pyridyl or pyrazyl)-L-4-(N,N-dimethylcarbamyloxy)phenylalanine compounds | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1144388-B1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | ELAN PHARM INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-7605166-B2 | Synergistic mixture of methotrexate and integrin antigen or antibody | ELAN PHARMACEUTICALS INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-7576101-B2 | Using sulfonamides such as N-[N-(3-pyridinesulfonyl)-L-3,3-dimethyl-4-thiaprolyl]-O-[1-methylpiperazin-4-ylcarbonyl]-L-tyrosine isopropyl ester optionally with immunoglobulins, steroids, antiinflammatory agents | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2009077052-A2 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-06-25 | — | — | WO | disclosed |
| EP-1635822-A4 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARM INC (US) | 2009-06-24 | — | — | EP | disclosed |
| US-7538215-B2 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1592387-A4 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARM INC (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7452912-B2 | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20080182850-A1 | 3-(HETEROARYL)ALANINE DERIVATIVES-INHIBITORS OF LEUKOCYTE ADHESION MEDIATED BY VLA-4 | WYETH | 2008-07-31 | — | — | US | disclosed |
| US-7378529-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | WYETH (US) | 2008-05-27 | — | — | US | disclosed |
| US-7365073-B2 | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7320960-B2 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1144384-B1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2007-10-31 | — | — | EP | disclosed |
| US-7288526-B2 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| EP-1635871-A4 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARM INC (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1592386-A4 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARM INC (US) | 2007-06-13 | — | — | EP | disclosed |
| US-7229970-B2 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7223762-B2 | Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070099921-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS | 2007-05-03 | — | — | US | disclosed |
| CN-1942161-A | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | ELAN PHARM INC (US) | 2007-04-04 | — | — | CN | disclosed |
| EP-1763361-A2 | STEROID SPARING AGENTS AND THEIR USE | Elan Pharmaceuticals, Inc. (US) | 2007-03-21 | — | — | EP | disclosed |
| US-7166580-B2 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7132418-B2 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-7115768-B2 | Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-7101855-B2 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060148046-A1 | Enzymatic process for the preparation of an intermediate compound and use thereof for the synthesis of tamsulosin hydrochloride | QUIMICA SINTETICA, S.A. | 2006-07-06 | — | — | US | disclosed |
| WO-2006070285-A2 | ENZYMATIC PREPARATION OF AN INTERMEDIATE COMPOUND FOR THE SYNTHESIS OF TAMSULOSIN | QUIMICA SINTETICA, S.A. (ES) | 2006-07-06 | — | — | WO | disclosed |
| EP-1001974-B1 | 4-AMINO-PHENYLALANINE TYPE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-7049306-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4. | ELAN PHARMACEUTICALS, INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-7045629-B2 | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane | MERCK PATENT GMBH (DE) | 2006-05-16 | — | — | US | disclosed |
| US-7030114-B1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1144435-B1 | PYROGLUTAMIC ACID DERIVATIVES AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060074110-A1 | Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2006-04-06 | — | — | US | disclosed |
| EP-1635822-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | Elan Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1635871-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | Elan Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-7005433-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2006-02-28 | — | — | US | disclosed |
| US-6998233-B2 | Methods for ligand discovery | SUNESIS PHARMACEUTICALS, INC. (US) | 2006-02-14 | — | — | US | disclosed |
| US-20060004019-A1 | Steroid sparing agents and methods of using same | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2006-01-05 | — | — | US | disclosed |
| EP-1612215-A1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | disclosed |
| CN-1231212-C | Polycyclic compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAN PHARM INC (US) | 2005-12-14 | — | — | CN | disclosed |
| US-20050261293-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | WYETH | 2005-11-24 | — | — | US | disclosed |
| EP-1592386-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | Elan Pharmaceuticals, Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1592387-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | Elan Pharmaceuticals, Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2005097162-A2 | STEROID SPARING AGENTS AND THEIR USE | ELAN PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-6953802-B2 | Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050222119-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | WYETH | 2005-10-06 | — | — | US | disclosed |
| US-20050215565-A1 | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | BIOGEN MA INC. | 2005-09-29 | — | — | US | disclosed |
| US-6949570-B2 | Carboxyalkyl substituted sulfonamidomethyl amides or ureas used for treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, and diabetes | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050203093-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS | 2005-09-15 | — | — | US | disclosed |
| US-20050192280-A1 | Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2005-09-01 | — | — | US | disclosed |
| EP-1144364-B1 | MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050142614-A1 | Methods for ligand discovery | WELLS JIM (US) | 2005-06-30 | — | — | US | disclosed |
| US-6911439-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2005-06-28 | — | — | US | disclosed |
| US-6903088-B2 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-6900179-B2 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2005-05-31 | — | — | US | disclosed |
| US-20050085459-A1 | Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | KONRADI ANDREI W (US) | 2005-04-21 | — | — | US | disclosed |
| US-20050074451-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| US-20050069541-A1 | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2005-03-31 | — | — | US | disclosed |
| EP-1446496-A4 | METHODS FOR LIGAND DISCOVERY | SUNESIS PHARMACEUTICALS INC (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | US | disclosed |
| US-20050014818-A1 | Process for producing optically active chroman derivative and intermediate | KANEKA CORPORATION (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1495044-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. Uriach y Compania S.A. (ES) | 2005-01-12 | — | — | EP | disclosed |
| WO-2005000246-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2005000244-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040266763-A1 | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| US-6803370-B2 | COMPOUNDS FOR USE IN THE TREATMENT OF ASTHMA, ALZHEIMER'S, DIABETES, ATHEROSCLEROSIS, INFLAMMATORY BOWEL DISEASE, ARTHRITIS, TUMOR METASTASIS, ISCHEMIA AND BRAIN DISORDERS | ELAN PHARMACEUTICALS, INC. | 2004-10-12 | — | — | US | disclosed |
| US-6794506-B2 | TREATMENT OF INFLAMMATORY DISEASES, SUCH AS ASTHMA, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, AIDS DEMENTIA, DIABETES, INFLAMMATORY BOWEL DISEASE, RHEUMATOID ARTHRITIS, TISSUE TRANSPLANTATION, TUMOR METASTASIS | ELAN PHARMACEUTICALS, INC. | 2004-09-21 | — | — | US | disclosed |
| EP-1452532-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| EP-1446496-A2 | METHODS FOR LIGAND DICOVERY | Sunesis Pharmaceuticals, Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2004066932-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARMACEUTICALS INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| WO-2004066931-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARMACEUTICALS INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| EP-1445324-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMAN DERIVATIVE AND INTERMEDIATE | KANEKA CORPORATION (JP) | 2004-08-11 | — | — | EP | disclosed |
| US-20040147512-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20040138266-A1 | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane | MERCK PATENT GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
| EP-1421063-A1 | DISULFIDE AND THIOSULFONATE LIGANDS AND LIBRARIES COMPRISING THESE LIGANDS | Sunesis Pharmaceuticals, Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| EP-1000051-B1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2004-05-19 | — | — | EP | disclosed |
| EP-1404325-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040043426-A1 | Methods for ligand discovery | WELLS JIM (US) | 2004-03-04 | — | — | US | disclosed |
| US-20040029873-A1 | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-02-12 | — | — | US | disclosed |
| US-20040014677-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-01-22 | — | — | US | disclosed |
| US-20040006093-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-01-08 | — | — | US | disclosed |
| WO-2003084984-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. URIACH Y COMPANIA S.A. (ES) | 2003-10-16 | — | — | WO | disclosed |
| US-20030166575-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN MA INC. | 2003-09-04 | — | — | US | disclosed |
| US-20030144328-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | KONRADI ANDREI W (US) | 2003-07-31 | — | — | US | disclosed |
| US-20030139402-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated byVLA-4 | KONRADI ANDREI W (US) | 2003-07-24 | — | — | US | disclosed |
| US-20030134874-A1 | Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | GRANT FRANCINE S (US) | 2003-07-17 | — | — | US | disclosed |
| US-20030125324-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | KONRADI ANDREI W (US) | 2003-07-03 | — | — | US | disclosed |
| US-6586602-B2 | CD antigen antagonists such as N-(methanesulfonyl)-L-prolyl-L-phenylalanine and prodrugs used as antiinflammatory agents | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-07-01 | — | — | US | disclosed |
| US-6583139-B1 | Treatment of inflammatory diseases; inflammatory brain diseases such as multiple sclerosis; N-(Toluene-4-sulfonyl)-L-prolyl-4-(alpha -methylbenzyloxy)-L-phenylalanine; Very Late Antigen 4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-06-24 | — | — | US | disclosed |
| WO-2003046200-A2 | METHODS FOR LIGAND DISCOVERY | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-6559127-B1 | Intercellular adhesion mediated by VLA-4 and other cell surface receptors is associated with a number of inflammatory responses | ATHENA NEUROSCIENCES, INC. | 2003-05-06 | — | — | US | disclosed |
| US-6545003-B1 | Treating asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. | ELAN PHARMACEUTICALS, INC. | 2003-04-08 | — | — | US | disclosed |
| US-20030065185-A1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-04-03 | — | — | US | disclosed |
| US-20030065193-A1 | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-04-03 | — | — | US | disclosed |
| US-6525026-B2 | Antiinflammatory agents; cardiovascular disorders; rheumatic diseases | ELAN PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| WO-2003014072-A1 | DISULFIDE AND THIOSULFONATE LIGANDS AND LIBRARIES COMPRISING THESE LIGANDS | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| US-20030027771-A1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-02-06 | — | — | US | disclosed |
| US-20030027850-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ASHWELL SUSAN (US) | 2003-02-06 | — | — | US | disclosed |
| US-20030017993-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | WYETH | 2003-01-23 | — | — | US | disclosed |
| US-20030008829-A1 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | COSTANZO MICHAEL J (US) | 2003-01-09 | — | — | US | disclosed |
| US-20020193312-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2002-12-19 | — | — | US | disclosed |
| US-6492421-B1 | BINDING VERY LATE ANTIGEN-4; INFLAMMATORY DISEASES SUCH AS ASTHMA, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, AIDS, DEMENTIA, DIABETES, INFLAMMATORY BOWEL DISEASE, RHEUMATOID ARTHRITIS, TISSUE TRANSPLANTATION, TUMOR METASTASIS, MYOCARDIAL ISCHEMIA | ATHENA NEUROSCIENCES, INC. | 2002-12-10 | — | — | US | disclosed |
| US-6492372-B1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| WO-2002096420-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| US-6489300-B1 | INHIBITORS OF ADHESION IN THE TREATMENT OF INFLAMMATORY BRAIN DISEASES AND OTHER INFLAMMATORY CONDITIONS | ELAN PHARMACEUTICALS, INC. | 2002-12-03 | — | — | US | disclosed |
| US-6479492-B1 | TREATMENT OF INFLAMMATORY DISEASES IN A MAMMALIAN PATIENT | ELAN PHARMACEUTICALS, INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020155505-A1 | Methods for ligand discovery | SUNESIS PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
| US-6469036-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES ASSOCIATED WITH THE RESPIRATORY TRACT, SUCH AS ASTHMA AND ALLERGIC RHINITIS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-22 | — | — | US | disclosed |
| US-6465513-B1 | SUCH AS N-(ADAMANT-1-YLCARBONYL)-L-4-(N,N-DIMETHYLCARBAMYL-OXY)PHENYLALANINE; INFLAMMATORY DISEASES SUCH AS ASTHMA, AIDS DEMENTIA, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, DIABETES, INFLAMMATORY BOWEL DISEASE, RHEUMATOID ARTHRITIS | ELAN PHARMACEUTICALS, INC. | 2002-10-15 | — | — | US | disclosed |
| US-6436904-B1 | TREATMENT OF INFLAMMATORY DISEASES IN MAMMALS | ELAN PHARMACEUTICALS, INC. | 2002-08-20 | — | — | US | disclosed |
| US-6423688-B1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ATHENA NEUROSCIENCES, INC. | 2002-07-23 | — | — | US | disclosed |
| US-6407066-B1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2002-06-18 | — | — | US | disclosed |
| US-20020058664-A1 | Beta-amino acid derivatives--inhibitors of leukocyte adhesion mediated by VLA-4 | WYETH | 2002-05-16 | — | — | US | disclosed |
| US-20020052470-A1 | Alpha amino acid derivatives--inhibitors of leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2002-05-02 | — | — | US | disclosed |
| US-20020052375-A1 | 3-(Heteroaryal) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2002-05-02 | — | — | US | disclosed |
| US-6362341-B1 | ANTIINFLAMMATORY AGENTS | ATHENA NEUROSCIENCES, INC. | 2002-03-26 | — | — | US | disclosed |
| WO-2002008201-A2 | BETA-AMINO ACID DERIVATIVES-INHIBITORS OF LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2002008202-A2 | ALPHA AMINO ACID DERIVATIVES--INHIBITORS OF LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| EP-1150997-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| EP-1147091-A2 | FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1147097-A1 | PEPTIDYL HETEROCYCLIC KETONES USEFUL AS TRYPTASE INHIBITORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1144435-A2 | PYROGLUTAMIC ACID DERIVATIVES AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1144364-A2 | MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1144388-A1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1144384-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6291453-B1 | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 | ATHENA NEUROSCIENCES, INC. | 2001-09-18 | — | — | US | disclosed |
| EP-1105112-A2 | COMPOSITIONS AND USES FOR VISION AND MEMORY DISORDERS | GPI NIL Holdings, Inc. (US) | 2001-06-13 | — | — | EP | disclosed |
| US-6225306-B1 | PYRROLO(1,2A)QUINOXALINES | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 2001-05-01 | — | — | US | disclosed |
| CN-1265670-A | Dipeptides and related compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | disclosed |
| WO-2000044733-A1 | PEPTIDYL HETEROCYCLIC KETONES USEFUL AS TRYPTASE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000043372-A1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000043413-A2 | PYROGLUTAMIC ACID DERIVATIVES AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000043371-A2 | FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000043369-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000043354-A2 | MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000043415-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000009107-A3 | SULFONAMIDES OF N-CONTAINING HETEROCYCLIC THIOESTERS FOR VISION AND MEMORY DISORDERS | GUILFORD PHARM INC (US) | 2000-06-15 | — | — | WO | disclosed |
| EP-1001971-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| EP-1001972-A1 | SUBSTITUTED PHENYLALANINE TYPE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| EP-1001973-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| EP-1001975-A1 | BENZYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| EP-1001974-A1 | 4-AMINO-PHENYLALANINE TYPE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| EP-1000051-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0994895-A1 | DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0994896-A1 | SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0987266-A1 | BIPHENYL DERIVATIVES AND MEDICINAL COMPOSITIONS | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2000-03-22 | — | — | EP | disclosed |
| EP-0983054-A1 | HAIR GROWTH COMPOSITIONS AND USES | GPI NIL Holdings, Inc. (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-2000009107-A2 | SULFONAMIDES OF N-CONTAINING HETEROCYCLIC THIOESTERS FOR VISION AND MEMORY DISORDERS | GPI NIL HOLDINGS, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-2000009108-A2 | COMPOSITIONS AND USES FOR VISION AND MEMORY DISORDERS | GPI NIL HOLDINGS, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| EP-0559774-B1 | INDIVIDUAL STEREOISOMERS OF 7- 3-(1-AMINOALKYL)-1-PYRROLIDINYL]-QUINOLONES AND NAPHTHYRIDONES AS ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 1999-07-07 | — | — | EP | disclosed |
| EP-0909759-A2 | Individual stereoisomers of 7-(3-aminoalkyl)-1-pyrrolidinyl)-quinolones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1999-04-21 | — | — | EP | disclosed |
| WO-1999006437-A1 | SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006434-A1 | 4-AMINO-PHENYLALANINE TYPE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006433-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006435-A1 | DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006436-A1 | BENZYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006432-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006431-A1 | SUBSTITUTED PHENYLALANINE TYPE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006390-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1998055090-A1 | HAIR GROWTH COMPOSITIONS AND USES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-12-10 | — | — | WO | disclosed |
| JP-H1036327-A | PRODUCTION OF OPTICALLY ACTIVE ISOMER OF 1-(3-METHOXYPHENYL)ETHYLAMINE | SUMITOMO CHEM CO LTD | 1998-02-10 | — | — | JP | disclosed |
| JP-H09286763-A | PRODUCTION OF OPTICALLY ACTIVE ISOMER OF 1-ALKYL-2-(SUBSTITUTED PHENYL)ETHYLAMINES | SUMITOMO CHEM CO LTD | 1997-11-04 | — | — | JP | disclosed |
| US-5633264-A | Individual stereoisomers of 7-[3-(1-aminoalkyl)-1-pyrrolidinyl]-Quinolones and naphthyridones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1997-05-27 | — | — | US | disclosed |
| US-5563155-A | QUINOLONE ANTIBIOTICS WITH INCREASED EFFICACY, REDUCED SIDE EFFECTS | WARNER-LAMBERT COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0390135-B1 | Pyrroloquinoline derivatives, antimicrobial agents using the same and process for preparing the same | OTSUKA PHARMA CO LTD (JP) | 1996-06-05 | — | — | EP | disclosed |
| US-5461165-A | Individual stereoisomers of intermediates of 7-[3-(1-aminoalkyl)-1-pyrrolidinyl]-quinolones and naphthyridones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1995-10-24 | — | — | US | disclosed |
| US-5344940-A | Bactericides | WARNER-LAMBERT COMPANY (US) | 1994-09-06 | — | — | US | disclosed |
| EP-0420120-B1 | Optically active benzyl alcohol compound and pharmaceutical composition | HOKURIKU PHARMACEUTICAL (JP) | 1994-08-31 | — | — | EP | disclosed |
| EP-0273399-B1 | Optically active 2,3-dihydrobenzoaxine derivatives and process for preparing the same | DAIICHI SEIYAKU CO (JP) | 1994-08-17 | — | — | EP | disclosed |
| US-5273998-A | Process for making an optically active 3,4-dihydro-3,4-epoxy-2H-1-benzopyran compound | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1993-12-28 | — | — | US | disclosed |
| US-5258528-A | Bactericides | WARNER-LAMBERT COMPANY (US) | 1993-11-02 | — | — | US | disclosed |
| EP-0559774-A1 | INDIVIDUAL STEREOISOMERS OF 7- 3-(1-AMINOALKYL)-1-PYRROLIDINYL]-QUINOLONES AND NAPHTHYRIDONES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-09-15 | — | — | EP | disclosed |
| US-5185337-A | Pyrroloquinoline derivatives and pharmaceutical compositions for antimicrobial use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-02-09 | — | — | US | disclosed |
| EP-0206283-B1 | OPTICALLY ACTIVE PYRIDOBENZOXAZINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-01-27 | — | — | EP | disclosed |
| US-5177216-A | DIASTEREOMERIC ESTER COMPOUND USEFUL AS AN INTERMEDIATE IN THE MAKING OF AN OPTICALLY ACTIVE 3,4-DIHYDRO-3,4-EPOXY-2H-1-BENZOPYRAN COMPOUND | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1993-01-05 | — | — | US | disclosed |
| US-5142046-A | Optically active pyridobenzoxazine derivatives and intermediates thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1992-08-25 | — | — | US | disclosed |
| EP-0331943-B1 | PHENOXYETHYLAMINE DERIVATIVES, PROCESS FOR PREPARING THE SAME, AND COMPOSITION FOR EXHIBITING EXCELLENT ALPHA-1-BLOCKING ACTIVITY CONTAINING THE SAME | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1992-06-17 | — | — | EP | disclosed |
| WO-1992009596-A1 | INDIVIDUAL STEREOISOMERS OF 7-[3-(1-AMINOALKYL)-1-PYRROLIDINYL]-QUINOLONES AND NAPHTHYRIDONES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1992-06-11 | — | — | WO | disclosed |
| EP-0456266-A1 | Method for preparing optically active 3,4-dihydro-3,4-epoxy-2H-1-benzopyran compounds, intermediates therefor and uses thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1991-11-13 | — | — | EP | disclosed |
| US-5053407-A | OPTICALLY ACTIVE PYRIDOBENZOXAZINE DERIVATIVES AND ANTI-MICROBIAL USE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1991-10-01 | — | — | US | disclosed |
| US-4985557-A | OFLOXACIN INTERMEDIATE | DAIICHI SEIYAKU CO., LTD. (JP) | 1991-01-15 | — | — | US | disclosed |
| US-4971990-A | HYPOTENSIVE AGENTS, DYSUREA | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1990-11-20 | — | — | US | disclosed |
| EP-0390135-A1 | Pyrroloquinoline derivatives, antimicrobial agents using the same and process for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-03 | — | — | EP | disclosed |
| US-4895944-A | BACTERICIDE OFLOXACIN | DAIICHI SEIYAKU COMPANY, LTD. (JP) | 1990-01-23 | — | — | US | disclosed |
| JP-H01287086-A | PYRIDOBENZOXAZINES | DAI ICHI SEIYAKU CO LTD | 1989-11-17 | — | — | JP | disclosed |
| EP-0331943-A1 | Phenoxyethylamine derivatives, process for preparing the same, and composition for exhibiting excellent alpha-1-blocking activity containing the same | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1989-09-13 | — | — | EP | disclosed |
| EP-0273399-A1 | Optically active 2,3-dihydrobenzoaxine derivatives and process for preparing the same | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1988-07-06 | — | — | EP | disclosed |
| EP-0206283-A2 | Optically active pyridobenzoxazine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1986-12-30 | — | — | EP | disclosed |
| US-4596819-A | Antidepressive agents | WARNER-LAMBERT COMPANY (US) | 1986-06-24 | — | — | US | disclosed |
| US-4217130-A | DECREASING ACID CONTENT WITH PHENYL- OR BENZYLCARBAMOYLPROLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1980-08-12 | — | — | US | disclosed |
| US-4217130-A | DECREASING ACID CONTENT WITH PHENYL- OR BENZYLCARBAMOYLPROLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1980-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043426-A1 | Methods for ligand discovery | ADGRF1, VCAM1, LDLR | ALDH1A1 1677/4885HTT 2011/4885GAA 3405/4885 |
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | ALDH1A1 1183/4885HTT 1548/4885GAA 674/4885 |
| US-20030139402-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated byVLA-4 | VCAM1, ICAM1, ITGB4 | ALDH1A1 386/4885HTT 1589/4885GAA 2410/4885 |
| US-20030017993-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | ALDH1A1 667/4885HTT 3803/4885GAA 2205/4885 |
| US-20150057328-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | ALDH1A1 1853/4885HTT 492/4885GAA 1886/4885 |
| US-20020193312-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | ALDH1A1 667/4885HTT 3803/4885GAA 2205/4885 |
| US-20020058664-A1 | Beta-amino acid derivatives--inhibitors of leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ALDH1A1 490/4885HTT 3328/4885GAA 2352/4885 |
| US-20070099921-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ALDH1A1 260/4885HTT 1502/4885GAA 2099/4885 |
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | TRPV3, TRPV2, TRPV1 | ALDH1A1 3317/4885HTT 2028/4885GAA 3441/4885 |
| US-20170107205-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 1786/4885HTT 1153/4885GAA 347/4885 |
| US-20130245010-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 1991/4885HTT 1028/4885GAA 339/4885 |
| US-20040029873-A1 | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, LTB4R | ALDH1A1 362/4885HTT 2412/4885GAA 2613/4885 |
| US-20050261293-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | ALDH1A1 322/4885HTT 3592/4885GAA 1632/4885 |
| US-20150190390-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 1836/4885HTT 1520/4885GAA 419/4885 |
| US-20050085459-A1 | Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | ALDH1A1 474/4885HTT 3286/4885GAA 2543/4885 |
| US-20030144328-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | ALDH1A1 322/4885HTT 3592/4885GAA 1632/4885 |
| US-20130237569-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 1991/4885HTT 1028/4885GAA 339/4885 |
| US-10030003-B2 | Synthesis of isoflavanes and intermediates thereof | CYP4B1, CYP51A1, CYP4A11 | ALDH1A1 752/4885HTT 4009/4885GAA 3138/4885 |
| US-20200270202-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | GOT1, ACAT1, GOT2 | ALDH1A1 1848/4885HTT 678/4885GAA 8/4885 |
| US-20040266763-A1 | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | VCAM1, AADAT, ICAM1 | ALDH1A1 376/4885HTT 3529/4885GAA 1398/4885 |
| US-20170283389-A1 | Synthesis of Isoflavanes and Intermediates Thereof | CYP4B1, CYP51A1, CYP4A11 | ALDH1A1 752/4885HTT 4009/4885GAA 3138/4885 |
| US-20040014677-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ALDH1A1 631/4885HTT 3788/4885GAA 2179/4885 |
| US-20100160341-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, ICAM1, ITGB4 | ALDH1A1 260/4885HTT 1502/4885GAA 2099/4885 |
| US-20130296364-A1 | MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 1985/4885HTT 1340/4885GAA 387/4885 |
| US-20050215565-A1 | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | MAG, PMP22, GAP43 | ALDH1A1 4370/4885HTT 3667/4885GAA 3071/4885 |
| US-20030125324-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ALDH1A1 260/4885HTT 1502/4885GAA 2099/4885 |
| US-20050203093-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ALDH1A1 260/4885HTT 1502/4885GAA 2099/4885 |
| US-20020155505-A1 | Methods for ligand discovery | ADGRF1, VCAM1, LDLR | ALDH1A1 1677/4885HTT 2011/4885GAA 3405/4885 |
| US-20050069541-A1 | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | MAG, PMP22, GAP43 | ALDH1A1 4370/4885HTT 3667/4885GAA 3071/4885 |
| US-20030134874-A1 | Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | ALDH1A1 258/4885HTT 3395/4885GAA 2037/4885 |
| US-20030008829-A1 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | CMA1, TPSB2, TPSAB1 | ALDH1A1 1904/4885HTT 1988/4885GAA 932/4885 |
| US-20030027850-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | ALDH1A1 414/4885HTT 3900/4885GAA 2784/4885 |
| US-20030065193-A1 | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ALDH1A1 369/4885HTT 4042/4885GAA 1617/4885 |
| US-20150065500-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | ALDH1A1 1786/4885HTT 1153/4885GAA 347/4885 |
| US-20130150424-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | ALDH1A1 1853/4885HTT 492/4885GAA 1886/4885 |
| US-20150246021-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | ALDH1A1 1831/4885HTT 508/4885GAA 1914/4885 |
| US-20110172229-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 1786/4885HTT 1153/4885GAA 347/4885 |
| US-20040147512-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ALDH1A1 260/4885HTT 1502/4885GAA 2099/4885 |
| US-20060004019-A1 | Steroid sparing agents and methods of using same | IL5, FCER2, CD40 | ALDH1A1 1053/4885HTT 3572/4885GAA 3878/4885 |
| US-20100311976-A1 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | HNMT, PNMT, INMT | ALDH1A1 87/4885HTT 1486/4885GAA 1594/4885 |
| US-20050222119-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | ALDH1A1 667/4885HTT 3803/4885GAA 2205/4885 |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | ALDH1A1 445/4885HTT 4486/4885GAA 3186/4885 |
| US-20080182850-A1 | 3-(HETEROARYL)ALANINE DERIVATIVES-INHIBITORS OF LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, AADAT, ICAM1 | ALDH1A1 376/4885HTT 3529/4885GAA 1398/4885 |
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | ALDH1A1 1490/4885HTT 1397/4885GAA 281/4885 |
| US-20040138266-A1 | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane | PAH, HPD, CYP3A43 | ALDH1A1 263/4885HTT 3941/4885GAA 1269/4885 |
| US-20050192280-A1 | Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ALDH1A1 439/4885HTT 3351/4885GAA 2298/4885 |
| US-20020052375-A1 | 3-(Heteroaryal) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGAL | ALDH1A1 572/4885HTT 3169/4885GAA 1744/4885 |
| US-20050014818-A1 | Process for producing optically active chroman derivative and intermediate | CYP8B1, CYP3A43, HPD | ALDH1A1 350/4885HTT 457/4885GAA 771/4885 |
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | GOT1, ACAT1, GOT2 | ALDH1A1 1848/4885HTT 678/4885GAA 8/4885 |
| US-20030065185-A1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, IL4I1 | ALDH1A1 1219/4885HTT 3876/4885GAA 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.